Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 6/20 | 0.41 |
| ▸ | OGG1 | O15527 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720803 | 1.00 | BTN3A1 (0.41) | BTN3A1OGG1CYP2D6CYP1A2ADRB2 | |
| SCHEMBL1273006 | 0.89 | BTN3A1 (0.45) | BTN3A1OGG1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL14941789 | 0.89 | ALDH1A1 (0.39) | BTN3A1OGG1NR2E1ALDH1A1MAPK1 | |
| SCHEMBL14941788 | 0.89 | ALDH1A1 (0.39) | BTN3A1OGG1NR2E1ALDH1A1MAPK1 | |
| SCHEMBL30628342 | 0.88 | ALDH1A1 (0.43) | BTN3A1OGG1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL22582156 | 0.88 | ALDH1A1 (0.43) | BTN3A1OGG1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL12274119 | 0.88 | ALDH1A1 (0.43) | BTN3A1OGG1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL723907 | 0.87 | HTT (0.41) | BTN3A1OGG1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL10208163 | 0.87 | ALDH1A1 (0.40) | BTN3A1OGG1NR2E1ALDH1A1MAPK1 | |
| SCHEMBL10208172 | 0.87 | HTT (0.41) | BTN3A1OGG1ALDH1A1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| EP-3797782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Janssen BioPharma, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9862743-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-9603863-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170037075-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | BTN3A1 4056/4885OGG1 220/4885CYP2D6 2173/4885 |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | BTN3A1 4056/4885OGG1 220/4885CYP2D6 2173/4885 |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | BTN3A1 4601/4885OGG1 428/4885CYP2D6 2785/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | BTN3A1 4056/4885OGG1 220/4885CYP2D6 2173/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | BTN3A1 1701/4885OGG1 490/4885CYP2D6 1864/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | BTN3A1 2837/4885OGG1 556/4885CYP2D6 3296/4885 |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | BTN3A1 3327/4885OGG1 404/4885CYP2D6 1152/4885 |
| US-20170037075-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | BTN3A1 4056/4885OGG1 220/4885CYP2D6 2173/4885 |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | BTN3A1 3191/4885OGG1 355/4885CYP2D6 3004/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | BTN3A1 1701/4885OGG1 490/4885CYP2D6 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.